{
}
Recursion Pharmaceuticals (RXRX) reported a Q3 loss of $0.34 per share, missing estimates by 3.03%, and revenues of $26.08 million, falling short of expectations by 24.86%. The company has seen a 30.8% decline in shares this year, while the S&P 500 gained 21.2%. Current consensus estimates for the next quarter are -$0.39 EPS on $12.29 million in revenues.
[SEC's website]
Recursion Pharmaceuticals Inc (RXRX) is set to release its Q3 2024 earnings on November 6, with revenue expected at $29.84 million and a loss of $0.37 per share. For the full year, revenue estimates have risen to $69 million, with a projected loss of $1.63 per share. Analysts have set a 12-month average price target of $10.14, indicating a potential upside of 53.22% from the current price of $6.62.
Eli Lilly has partnered with AI firm Insitro to advance drug development, focusing on metabolic diseases. The collaboration includes three agreements, allowing Insitro to retain global rights to its research while Lilly benefits from milestone payments and potential royalties. Insitro will utilize Lilly's delivery technology alongside its own innovations to target liver conditions and develop new treatments.
Recursion Pharmaceuticals, Inc.
Companies
| Symbol | RXRX |
| Name | Recursion Pharmaceuticals, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | UT |
| City | Salt Lake City |
| Zipcode | 84101 |
| Website | http://www.recursion.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
recursion pharmaceuticals reports q3 loss and misses revenue estimates
00:55 07.11.2024
recursion and exscientia announce proposed business combination and proxy statement details
22:15 06.11.2024
recursion pharmaceuticals set to report q3 2024 earnings with revenue estimates rising
09:00 05.11.2024
lilly and insitro forge partnership to advance metabolic disease treatments using ai
Eli Lilly and Company
Bristol-Myers Squibb Company
NVIDIA Corporation
Gilead Sciences, Inc.
Recursion Pharmaceuticals, Inc.
USA
Show more
13:29 09.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Government Economic Policies
Retail and Consumer Goods
Supply Chain Management
Industry Mergers & Acquisitions
Stock Market Updates
Energy Sector Developments
Venture Capital Investments
Global Financial Events
Finance Mergers & Acquisitions
Central Bank Actions
Cryptocurrency & Blockchain Regulations
Emerging Startups
Funding Rounds & Investments
Inflation and Monetary Impact
Private Equity Deals
Market Analysis and Predictions
Countries:
Companies:
Apple Inc.
NVIDIA Corporation
Google Inc.
Dell Technologies Inc.
Samsung Securities Co.,Ltd.
Learning Resources Inc.
MGA Entertainment Inc.
XPeng Inc.
Toyota Motor Corp
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
Taiwan Semiconductor Manufacturing Company Limited
Microsoft Corporation
Verizon Communications Inc.
OpenAI ERC USD
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
Australian Dollar
United Arab Emirates Dirham
British Pound Sterling
New Taiwan Dollar
New Zealand Dollar
Vietnamese Đồng
South Korean Won
Egyptian Pound
Thai Baht
Saudi Riyal
Indonesian Rupiah
South African Rand
Malaysian Ringgit
Singapore Dollar
Lebanese Pound
People: